Actively Recruiting
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Led by Taisho Pharmaceutical Co., Ltd. · Updated on 2026-04-17
100
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
CONDITIONS
Official Title
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hyperphosphatemia patients receiving hemodialysis or hemodiafiltration three times a week for at least 12 weeks before Visit 1 (Week -3)
- Patients aged 18 years or older at the time of consent
- Serum phosphorus concentration between 5.5 mg/dL and less than 10.0 mg/dL at Visit 1 (Week -3)
- Prescribed at least one phosphate binder within the approved dosage with no changes in drug or dosage during the 2 weeks before Visit 1 (Week -3)
You will not qualify if you...
- Serum intact parathyroid hormone concentration greater than 500 pg/mL from Visit 1 (Week -3) to Visit 4 (Week 0)
- History of previous parathyroid intervention such as parathyroidectomy or percutaneous ethanol injection therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Actively Recruiting
Research Team
T
Taisho Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.
CONTACT
T
Taisho Director Taisho Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here